P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408). (23rd June 2022) - Loges, S.; Heuser, M.; Chromik, J.; Sutamtewagul, G.; Kapp-Schwoerer, S.; Crugnola, M.; Di Renzo, N.; Lemoli, R.; Mattei, D.; Ben-Batalla, I.; Waizenegger, J.; Rieckmann, L.-M.; et al.